(Press-News.org) Researchers from Mass General Brigham have unveiled the results of a large clinical trial that found that adding the drug evolocumab to patients’ treatment significantly reduced the risk of major adverse cardiovascular events in those who are at high risk. Results were presented today at the American Heart Association Scientific Sessions and simultaneously published in The New England Journal of Medicine.
“The results of this trial offer hope for preventing a first heart attack, stroke, or other cardiovascular event in patients who are at high risk,” said corresponding author Erin Bohula, MD, a cardiologist in the Mass General Brigham Heart and Vascular Institute. “Our findings reflect the promise of prevention strategies and reflect our ongoing commitment to conducting rigorous clinical trials to advance patient care with the goal of saving lives and improving quality of life.”
PCSK9 inhibitors, such as evolocumab, are designed to reduce LDL cholesterol, a major risk factor for cardiovascular events. Previous studies have found that PCSK9 inhibitors can prevent subsequent cardiovascular events in patients who have previously had a heart attack or stroke, but the current study—known as The Effect of EVolocumab in PatiEntS at High CArdiovascuLar RIsk WithoUt Prior Myocardial Infarction or Stroke (VESALIUS)-CV trial—is the first to study the drug’s preventive effects in people who have not previously had a heart attack or stroke.
The phase 3 trial was designed by the TIMI Study Group at Mass General Brigham, in conjunction with the trial sponsor and funder, Amgen, Inc. Participants who were enrolled from around the world had to have atherosclerosis or diabetes and LDL cholesterol levels above 90mg/dL. Importantly, participants were not eligible if they had previously had a heart attack or stroke. A total of 12,257 participants were randomly assigned to receive evolocumab (140 mg every two weeks) or a placebo, in addition to their standard care.
Participants were followed for a median of 4.6 years. During that time, 336 patients (6.2%) in the group that received evolocumab and 443 patients (8.0%) in the group that received placebo experienced coronary heart disease death, myocardial infarction, or ischemic stroke. Overall, this translates this to a 25% reduction in risk of one of these events. Moreover, the researchers report that compared to placebo, those taking evolocumab had a 36% reduction in heart attacks. In addition, a nominally lower rate of death was seen in the evolocumab arm (7.9% vs. 9.7%)
The authors note that while most patients in the trial were taking high-intensity statins or other cholesterol-lowering medications, some participants were on less intensive treatments or none at all. However, results were consistent regardless of patients’ other treatments. Most patients in the study were white, meaning that results may not be generalizable to all patient populations.
“In VESALIUS-CV, patients in the evolocumab arm achieved LDL-C levels of around 40 mg/dL. I believe that is what we should be targeting in these patients,” said Marc S. Sabatine, MD, MPH, Chair of the TIMI Study Group and the Lewis Dexter, MD, Endowed Chair in Cardiovascular Medicine at Brigham and Women's Hospital.
Authorship: In addition to Bohula, Mass General Brigham authors include Nicholas A. Marston, Jeong-Gun Park PhD1, Julia F. Kuder, Sabina A. Murphy, Robert P. Giugliano, and Marc S. Sabatine. Additional authors include Ajay K. Bhatia, Gaetano M. De Ferrari, Lawrence A. Leiter, Jose C. Nicolau, Emileigh Walsh, Huei Wang, Vladimir Blaha, Andrzej Budaj, Jan H. Cornel, Assen Goudev, Robert Gabor Kiss, Alberto J. Lorenzatti, Alexander Parkhomenko, Marcoli Cyrille, Gabriel Paiva da Silva Lim, and E. Magnus Ohman.
Disclosures:
Bohula and Sabatine are members of the TIMI Study Group. The TIMI Study Group reports grant support through Brigham and Women’s Hospital from Abbott, Amgen, Anthos Therapeutics, ARCA Biopharma, Inc., AstraZeneca, Boehringer Ingelheim, Daiichi-Sankyo, Ionis Pharmaceuticals, Inc., Marea; Merck, Novartis, Pfizer, Regeneron Pharmaceuticals, Inc., Roche, Saghmos Therapeutics, Siemens Healthcare Diagnostics, Inc., Softcell Medical Limited, Verve Therapeutics, and Zora Biosciences.
Bohula reports personal fees from Amgen, Celecor, Esperion, Kowa, Novo Nordisk, Servier, and Scleroderma Research Foundation. Sabatine reports personal fees from Amgen; AMPEL BioSolutions; Anthos Therapeutics; AstraZeneca; Beren Therapeutics; Boehringer Ingelheim; Canadian Cardiovascular Research Network; Dr. Reddy’s Laboratories; General Medicines; Merck; North American Thrombosis Foundation; Novo Nordisk; Precision BioSciences; and TigerMed.
Funding: Funded by Amgen, Inc.
Paper cited: Bohula EA et al. “Evolocumab in Patients without Prior Myocardial Infarction or Stroke” NEJM DOI: 10.1056/NEJMoa2514428
###
About Mass General Brigham
Mass General Brigham is an integrated academic health care system, uniting great minds to solve the hardest problems in medicine for our communities and the world. Mass General Brigham connects a full continuum of care across a system of academic medical centers, community and specialty hospitals, a health insurance plan, physician networks, community health centers, home care, and long-term care services. Mass General Brigham is a nonprofit organization committed to patient care, research, teaching, and service to the community. In addition, Mass General Brigham is one of the nation’s leading biomedical research organizations with several Harvard Medical School teaching hospitals. For more information, please visit massgeneralbrigham.org.
END
Researchers from Mass General Brigham have found that olezarsen—a drug designed to lower triglyceride levels—can also decrease the risk of acute pancreatitis, a potential complication in patients with severely elevated triglyceride levels. The results, from two randomized, placebo-controlled trials (CORE-TIMI 72a and CORE2-TIMI 72b), were presented at the American Heart Association Scientific Sessions and simultaneously published in The New England Journal of Medicine.
Severe hypertriglyceridemia is a condition in which the level of triglycerides (a type of fat that circulates in the blood) is very high. Approximately 1 in 100 people in the U.S. have severe hypertriglyceridemia. ...
Steatotic liver disease (SLD), mainly encompassing metabolic dysfunction-associated steatotic liver disease (MASLD), alcohol-related liver disease (ALD), and metabolic dysfunction and ALD (MetALD), has emerged as the dominant cause of chronic liver disease worldwide, displacing viral hepatitis as the primary aetiology. Globally, the prevalence of MASLD is estimated even over 30%, affecting over one-third of adults. Parallelly, alcohol remains a major risk factor, with heavy drinking contributing to 90–95% of SLD cases and up to 10% advancing to cancer.
Genetic ...
About The Study: The findings of this study support the routine use of sodium-glucose cotransporter 2 (SGLT2) inhibitors to improve kidney outcomes across the full spectrum of kidney function and albuminuria among patients with type 2 diabetes, chronic kidney disease, or heart failure.
Corresponding Authors: To contact the corresponding authors, email Brendon L. Neuen, PhD (bneuen@georgeinstitute.org.au) and Hiddo J. L. Heerspink, PhD (h.j.lambers.heerspink@umcg.nl).
To access the embargoed study: Visit our For The ...
In late-breaking presentations at the American Society of Nephrology Kidney Week meeting and simultaneously published in two companion papers in JAMA, the findings are based on data from over 70,000 participants across 10 major randomised controlled trials. The meta-analyses were conducted by the SGLT2 Inhibitor Meta-analysis Cardio-Renal Trialists’ Consortium (SMART-C), led by The George Institute for Global Health.
SGLT2 inhibitors, originally developed to treat type 2 diabetes, have since demonstrated substantial protection against heart failure and chronic ...
Despite effective HIV medication, the immune system of people with HIV remains disrupted in the long term. Researchers at Amsterdam UMC investigated whether this dysregulation can be prevented by starting HIV medication immediately after infection – i.e. within a few days. They saw that six months after this early treatment, the immune system did indeed work as in people without HIV. But in the longer term, the immune system was disrupted again. This is shown by research by Amsterdam UMC, published in the journal EBioMedicine.
Early treatment protects immune systems only temporarily
For this study, the scientists examined ...
Record numbers of men and women globally are now estimated to have reduced kidney function, a new study shows. Figures rose from 378 million people with the disease in 1990 to 788 million in 2023 as the world population grew and aged, making it for the first time a top 10 cause of death worldwide.
Led by researchers at NYU Langone Health, the University of Glasgow, and the Institute for Health Metrics and Evaluation (IHME) at the University of Washington, the analysis explored the rise of the illness, in which the kidneys gradually lose their ability to filter waste and excess fluid from the blood. Mild cases may have no symptoms while the most severe stages ...
In 2023, chronic kidney disease (CKD) was the 9th-leading cause of death worldwide, responsible for nearly 1.5 million deaths.
Unlike most other leading causes of death, CKD mortality rates continue to rise, signaling a growing global health crisis.
In 2023, CKD ranked as the 12th-leading cause of disability worldwide and the 7th-leading driver of cardiovascular deaths. Kidney dysfunction alone accounted for almost 12% of all global cardiovascular deaths.
Diabetes, obesity, and high blood pressure remain the top drivers of CKD, alongside dietary risks and environmental factors.
SEATTLE, Wash. – Nov. 7, ...
About The Study: The results of this study suggest that community health workers played a vital role in improving patient engagement, emotional wellbeing, and self-efficacy, suggesting their integration into dialysis care teams may enhance holistic, patient-centered care.
Corresponding Author: To contact the corresponding author, Lilia Cervantes, MD, email Lilia.Cervantes@cuanschutz.edu.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamanetworkopen.2025.48506)
Editor’s ...
About The Study: In this randomized clinical trial, a culturally tailored community health worker intervention modestly lowered interdialytic weight gain and improved dialysis adherence and patient activation among Hispanic and Latino patients with hemodialysis-dependent kidney failure.
Corresponding Author: To contact the corresponding author, Lilia Cervantes, MD, MSc, email lilia.cervantes@cuanschutz.edu.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamainternmed.2025.5305)
Editor’s Note: Please see the article for additional information, including other authors, author ...
As China’s most important grain-producing region, Northeast China plays a vital role in safeguarding national food security. Yet this agricultural powerhouse faces a growing dilemma: how to maintain high crop yields while protecting the fragile ecosystems that sustain long-term productivity. A new study published in Agricultural Ecology and Environment identifies the key conflicts between agricultural expansion and ecological protection in the region and proposes integrated strategies to achieve a more sustainable balance.
Over the past four decades, Northeast China’s farmlands ...
